Europe Breast Cancer Screening Market Analysis And Growth Forecast 2024-2032

Europe Breast Cancer Screening Market Analysis

The Europe Breast Cancer Screening Market is experiencing rapid growth, projected to reach US$ 2.21 billion by 2032, up from US$ 1.03 billion in 2023, with a robust CAGR of 8.85% from 2024 to 2032. This growth is being driven by a combination of factors, including increasing breast cancer cases, technological advancements in screening methods, heightened awareness, and the supportive role of government policies.

Request a free sample copy of the report: https://www.renub.com/europe-breast-cancer-screening-market-mammography-mri-and-ultrasound-forecast-to-2022-1097-p.php

Breast Cancer Screening Market Overview

Breast cancer remains one of the most prevalent cancers, especially among women. With more than 2 million new cases reported globally in 2019, breast cancer is the second most common cancer worldwide. In Europe, it is the most common cancer among women, with an estimated 565,500 cases in 2019 alone. This growing incidence of breast cancer is a major driver for the European breast cancer screening market.

As of recent statistics, the UK alone sees over 58,000 breast cancer diagnoses each year, with similar rates in other European countries such as Spain, Scotland, and Wales. Early detection through screening methods like mammograms is vital to improving survival rates, making the demand for screening technologies and services a top priority across the continent.

Key Drivers Fueling Market Growth

1. Increasing Prevalence of Breast Cancer

The rising incidence of breast cancer is one of the primary factors fueling the growth of the screening market in Europe. Factors such as unhealthy lifestyles, poor dietary habits, and increased alcohol consumption contribute to this rise. Additionally, longer life expectancies and genetic predispositions are leading to higher rates of breast cancer diagnoses, which in turn is increasing the demand for screening services.

According to EUROPA DONNA, the European Coalition Against Breast Cancer, 1 in 8 women in Europe will be diagnosed with breast cancer before the age of 85. This high rate of incidence ensures the continuous need for regular screening services, creating an expanding market for breast cancer diagnostic tools and treatments.

2. Government Support and Awareness Campaigns

Government initiatives to improve breast cancer awareness and provide access to screening services are crucial to the market’s growth. In Europe, national health services and nonprofit organizations often conduct free screening programs, helping to increase the number of people getting screened and fostering early detection. The NHS in the UK, for instance, has allocated millions in funding to expand breast cancer screening centers.

In addition, public awareness campaigns such as the “Breast Cancer Affects Us All” initiative in Germany aim to increase understanding and encourage more women to get screened. These campaigns not only help reduce the stigma around breast cancer but also educate women about the importance of early detection.

3. Technological Advancements in Screening Methods

Advancements in screening technologies are another key driver of the market. Innovations in mammography, such as digital mammography and 3D mammography, have improved the accuracy and efficiency of early detection. Additionally, technologies like MRI and ultrasound are being used alongside traditional mammograms to offer more comprehensive screening options, especially for women with dense breast tissue. The development of AI-powered diagnostic tools is also enhancing the ability to identify potential breast cancer earlier, making these technologies vital in screening programs.

4. Increased Focus on Clinical Trials and Research

Ongoing clinical trials and research are helping to further refine breast cancer screening methods. For example, a clinical trial in the Netherlands, supported by the University Medical Center in Utrecht, aims to compare the effectiveness of mammography plus MRI against mammography alone for women with dense breasts. The growing number of these clinical studies is expected to produce groundbreaking data that will enhance screening accuracy and efficacy, ultimately benefiting the market.

Germany’s Role in the European Breast Cancer Screening Market

Germany holds a significant share of the European breast cancer screening market, driven by a high incidence of breast cancer and increasing public awareness. Startups like Vara, based in Berlin, have made strides in improving access to breast cancer screening. By raising funds to hire experienced breast radiologists and introducing new, data-driven methods for screening, Vara is helping to make early detection more accessible.

Furthermore, German companies such as FUJIFILM Europe GmbH are also contributing to the market’s growth by launching advanced screening equipment. The company’s Harmony edition of the Amulet Innovality mammography system represents a leap forward in digital mammography technology, offering greater accuracy and efficiency in detecting breast cancer.

Key Companies Leading the Market

The Europe Breast Cancer Screening Market features several prominent players, including:

AstraZeneca
Novartis
Sanofi
Pfizer
Bayer AG
GlaxoSmithKline plc

These companies are at the forefront of research and development, bringing forth new drugs and diagnostic tools that are improving outcomes for breast cancer patients.

Key Market Developments

Several recent initiatives are shaping the market:

January 2023: The UK government allocated USD 12.2 million (GBP 10 million) to build 29 new breast cancer screening centers to accelerate the identification and treatment of breast cancer. This initiative will increase access to screening and improve early detection rates.
September 2022: The European Union (EU) funded the CanScreen-ECIS project, which aims to enhance cancer screening across Europe by modernizing the European Cancer Information System (ECIS). This initiative will improve the efficiency and scope of breast cancer screening programs in the region.

Challenges and Opportunities

While the European breast cancer screening market is growing, there are challenges to address. Access to screening services in rural areas, screening disparities between different socioeconomic groups, and screening hesitancy among certain populations need to be tackled. However, with continued innovation in screening technologies, increased government funding, and the growing availability of comprehensive screening programs, these challenges present opportunities for companies to develop solutions that promote equity and wider access.

Related Report :

Europe In-Vitro Diagnostics Market

Global Clinical Chemistry Analyzer Market

Global Radiology Information System Market

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)

Email: mailto:rajat@renub.com

Europe Breast Cancer Screening Market, Size, Forecast

Renub Research has recently published a report named “Europe Breast Cancer Screening Market, Size, Forecast 2022-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis” providing a detailed industry analysis that consists of market share insights. Furthermore, the report studies competitors and regions and the recent growth in the Europe Breast Cancer Screening Market.

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/europe-breast-cancer-screening-market-mammography-mri-and-ultrasound-forecast-to-2022-1097-p.php

The Europe Breast Cancer Screening Market is expected to experience a growth rate of approximately 3.19% from 2022 to 2028.At the moment, every European country provides some type of breast cancer screening. Nonetheless, there are differences in the state of implementation, attendance, and the scope of opportunistic screening. As a consequence, breast cancer screening has yet to fully realize its promise. Screening for breast, cervical, and colorectal cancer is recommended in the European Union when given as part of an organized program with enough resources for good quality. In the European Union, organized screening programs are encouraged since they employ a team of individuals who are responsible for ensuring the quality of the services supplied. This involves ensuring that rules are followed and that screening program findings are recorded and analysed on a regular basis.

The rising incidence of breast cancer, the existence of prominent companies in the European breast cancer screening market, and strong research and development are all driving the market’s expansion. Breast cancer affects around 58,000 women and 380 men in the United Kingdom each year. Every year, about 47,000 individuals in England are diagnosed with breast cancer. Every year, around 4,800 individuals in Scotland are diagnosed with breast cancer. Every year, roughly 2,900 individuals in Wales are diagnosed with breast cancer. Breast cancer is the most frequent cancer among women in the European area; with a frequency of 565,500 in 2019, according to EUROPA DONNA, the European Coalition against Breast Cancer, and 1 in 8 women in the European countries will have breast cancer by the age of 85. As a result, breast cancer strikes many women at their prime years, which is expected to fuel market development throughout the projected period.

𝑭𝒐𝒓 𝑴𝒐𝒓𝒆 𝑫𝒆𝒕𝒂𝒊𝒍𝒔, 𝑮𝒓𝒂𝒃 𝒕𝒉𝒆 Free Sample Report: https://www.renub.com/request-sample-page.php?gturl=europe-breast-cancer-screening-market-mammography-mri-and-ultrasound-forecast-to-2022-1097-p.php

The German Breast Cancer Screening market has expanded dramatically as a result of growing breast cancer incidence and greater women’s knowledge about early detection.

The difficulties of recognizing and treating cancers at late stages are driving up demand for early breast cancer diagnostics in Germany. The country’s wealth of diagnostic facilities, together with a well-established healthcare system, contributes greatly to the growth. Furthermore, with roughly 70,000 new cases each year, breast cancer is the most frequent cancer form among women in Germany. Despite breakthroughs in therapy, breast cancer still takes over 17,000 lives each year, emphasizing the need of comprehensive screening programs.While imaging and screening technologies have grown in popularity, the safety and accuracy of certain treatments are still being questioned for long-term usage. Due to a lack of evidence supporting its dependability and cost, genomic testing, next-generation sequencing, and blood tests have lower demand than imaging. Breast biopsy for diagnosis is predicted to gain prominence over time. The growing number of breast cancer patients, the development of cost-effective diagnostic methods, favourable government reimbursement policies, and the expansion of private diagnostic facilities are all projected to increase the German breast cancer diagnostics market.

Increasing consciousness, growing breast cancer incidence, and better healthcare infrastructure are the primary drivers driving the expansion of the Breast cancer mammography screening sector in Spain.

In Spain, breast cancer mammography screening is a vital part of healthcare, aiming for early detection and better outcomes for patients. X-rays are used to examine the breast for any cancer signs in women without symptoms. The program focuses on women aged 50-69, at higher risk. Success depends on awareness, accessibility to facilities, and support from the healthcare system and government. Regular screening is crucial for early detection, leading to improved treatment options and survival rates. Advancements in technology like digital mammography and 3D tomosynthesis enhance accuracy and efficiency in breast cancer detection.

The United Kingdom is experiencing significant growth in the Breast Cancer MRI Screening industry.

The United Kingdom (UK) is seeing substantial expansion in the Breast Cancer MRI Screening business. As knowledge about breast cancer and the need of early detection improves, more women are choosing for MRI tests. The UK’s healthcare infrastructure and availability to innovative medical technology contribute to the market’s development. MRI screens provide greater accuracy and sensitivity in identifying breast cancer, leading to better results for patients. With continued developments in MRI technology and greater focus on preventive healthcare, the UK is positioned as a fast developing market in breast cancer MRI screening, benefitting both patients and healthcare providers.

The Germany Breast Cancer Ultrasound Industry is undergoing remarkable expansion.

Germany’s well-developed healthcare infrastructure and devotion to patient care have further encouraged the acceptance of breast cancer ultrasonography. Healthcare practitioners are increasingly depending on ultrasound-guided biopsies to collect exact tissue samples for proper diagnosis and therapy planning. The industry’s development is also fuelled by an increasing focus on breast cancer awareness and frequent screening efforts. More women understand the value of early diagnosis, leading to rising demand for breast cancer ultrasound tests. Continuous research and improvements in ultrasound technology are boosting picture quality and diagnostic capabilities, further supporting the industry’s prospects in Germany.

Key Player

In the Europe Breast Cancer Screening Market, important firms such as AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc have substantial positions.

Types – Market has been covered from 3 viewpoints (Mammography Screening, MRI Screening and Ultrasound Screening)

Countries – 8 European Country Breast Cancer Screening Market has been Covered (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands)

Company Insights: (Overview, Recent Development &Sales Analysis)

Companies Covered in the Report: (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc)

Breast Cancer Screening Market, Size, Global Forecast 2023-2028

Prostate Cancer Diagnostics Market, Size, Global Forecast 2023-2028

Asia Cervical Cancer Screening Market, Size, Forecast 2023-2028

Europe Cervical Cancer Screening Market, Size, Forecast 2023-2028

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research Web: www.renub.com